STOCKWATCH: Onyx at the crossroads of value destruction
This article was originally published in Scrip
Apart from those under investigation by the US SEC for insider trading, Amgen’s exposed bid for Onyx Pharmaceuticals took most of us by surprise (scripintelligence.com, 01 July 2013). But now the intrigue for investors lies in watching the plot unfold, and seeing the choices that Onyx management and shareholders make.
You may also be interested in...
Considerable value has been assigned to the companies developing coronavirus vaccines. Multiple suppliers and a met clinical need may erode much of that value after the pandemic.
Lexicon’s announcement of two positive cardiovascular outcome studies was tempered by the realization that its drug is not approved in the US, nor in Europe in the diabetic populations studied.
Among big pharma there is a creeping realization that the effects of the coronavirus on revenues and prescriptions may linger. At smaller biotechs, it is patently obvious.